BSE filing, NSE: AMARDEE. Summary written from the filing by ALFA Finder's alert engine.
Amerise Biosciences Ltd: key numbers
- Share price
- ₹0.82
- Market cap
- ₹5.42 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.02 Cr
- P/E (TTM)
- -102.6×Sector 26.2×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amerise Biosciences Ltd
All →Amerise Biosciences Board Meeting Date
Amerise Biosciences will hold a board meeting on 30 October 2026 to consider Q2 and H1 FY27 unaudited results. This is an advance notice of a future meeting with no financial figures disclosed.
Amerise Biosciences Other Announcement
Amerise Biosciences Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
Amerise Biosciences Annual Report
Amerise Biosciences has submitted its Annual Report for the financial year 2024-25. The company scheduled its 41st Annual General Meeting for September 24, 2026.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Ltd has submitted the notice for its 41st Annual General Meeting, scheduled to be held on September 24, 2026.
Amerise Biosciences Capital Structure Change
Snehjeev Ventures Private Limited and PACs acquired 76,725 equity shares of Amerise Biosciences Ltd. The acquisition increases their aggregate stake from 10.92% to 11.04%.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.